SCIGEN DOUBLES ON CHINA DEAL

Shares in SciGen more than doubled after the biopharmaceutical company announced a $US145 million-plus ($192 million) distribution deal into China for its Hepatitis-B vaccine, its first foray into the country. The Singapore-based company, which is listed on the Australian Stock Exchange, has signed a non-exclusive agreement with China-based Hefei Life Science Park Investment and Development Company (HID). Under the commercialisation deal, HID has committed to order and pay for SciGen's Hepatitis-B vaccine - Sci-B-Vac - in either bulk antigen or dispensed dose form for the next seven years.

Australian Finance Review (http://afr.com/articles/2005/10/10/1128796446138.html)